Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-11-17 DOI:10.1080/07357907.2023.2278048

Ashish Singh, Josh Thomas Georgy, Anjana Joel, Divya Bala Thumaty, Ajoy Oommen John, Nithya Ramnath, Tarun K George, Parth Sharma, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko

{"title":"Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.","authors":"Ashish Singh, Josh Thomas Georgy, Anjana Joel, Divya Bala Thumaty, Ajoy Oommen John, Nithya Ramnath, Tarun K George, Parth Sharma, Shalom Patole, Grace Rebekah, Elanthenral Sigamani, Marie Therese Manipadam, Anish Jacob Cherian, Deepak Thomas Abraham, Mazhuvanchary Jacob Paul, Rajesh Balakrishnan, Patricia Sebastian, Selvamani Backianathan, Raju Titus Chacko","doi":"10.1080/07357907.2023.2278048","DOIUrl":null,"url":null,"abstract":"<p><p>We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients with early triple-negative breast cancer. This regimen achieved a high pathological complete response (ypT0/TisN0) rate of 55.2% and favorable survival outcomes (30-month event-free survival, 91.2%; overall survival, 97%). Febrile neutropenia was observed in 4.3% of patients, and 98% completed at least six of eight cycles. ddDCEP was more cost-effective than contemporary carboplatin-based regimens. This novel approach offers an economically viable and effective alternative to current chemoimmunotherapy regimens, and merits further investigation.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"789-802"},"PeriodicalIF":1.8000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2023.2278048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We assessed the efficacy, tolerability, and cost-effectiveness of a novel neoadjuvant regimen comprising docetaxel-cyclophosphamide alternating with epirubicin-cisplatin (ddDCEP) administered biweekly for 16 weeks in 116 patients with early triple-negative breast cancer. This regimen achieved a high pathological complete response (ypT0/TisN0) rate of 55.2% and favorable survival outcomes (30-month event-free survival, 91.2%; overall survival, 97%). Febrile neutropenia was observed in 4.3% of patients, and 98% completed at least six of eight cycles. ddDCEP was more cost-effective than contemporary carboplatin-based regimens. This novel approach offers an economically viable and effective alternative to current chemoimmunotherapy regimens, and merits further investigation.

查看原文本刊更多论文

剂量密集多西他赛-环磷酸胺和表柔比星-铂（ddDCEP）：116例早期三阴性乳腺癌癌症患者的替代含铂方案分析。

我们评估了一种新的新辅助方案的疗效、耐受性和成本效益，该方案包括多西他赛-环磷酰胺与表阿霉素-西铂（ddDCEP）交替用药，每两周给药16周，治疗116例早期癌症三阴性乳腺癌患者。该方案实现了55.2%的高病理完全缓解率（ypT0/TisN0）和良好的生存结果（30个月无事件生存率91.2%；总生存率97%）。4.3%的患者出现发热性中性粒细胞减少症，98%的患者至少完成了八个周期中的六个周期。ddDCEP比当代基于卡铂的方案更具成本效益。这种新方法为目前的化学免疫疗法提供了一种经济可行且有效的替代方案，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.